New drug GLR2037 enters early human testing for metastatic prostate cancer
NCT ID NCT07468396
First seen Mar 26, 2026 · Last updated Jun 15, 2026 · Updated 16 times
Summary
This early-stage study tests a new drug called GLR2037 in about 65 men with metastatic prostate cancer that has spread to bones or soft tissue. The main goal is to check the drug's safety and how the body processes it. Participants must have already tried hormone therapy and have castrate testosterone levels.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
No.8 Nanfeng West 1st Street, Huoxian, Tongzhou District
Beijing, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.